RxDoctor Payments Data

Alexander Massey, MD

Pulmonary Disease · Placerville, CANPI 1851463343

Payments from drug & device makers

$5,370in general payments, 2019–2025

Across 266 payments — averaging $20.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$758
  • GSK$683
  • AstraZeneca$500
  • Regeneron Healthcare Solutions, Inc.$449
  • United Therapeutics Corporation$417
  • Actelion Pharmaceuticals US, Inc.$360
  • plus $2K from 36 others

What the payments were for

  • Food & beverage$5,33599%
  • Education$341%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,370 in reported general payments places this provider in the 65th percentile of 1,261 pulmonary disease providers in California.

See all pulmonary disease providers in California

Medicare billing

Part B allowed, 2024
$74,294
Medicare patients
436
Services billed
969

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter247$212,457
Dupixent PenDupilumab28$102,459
Dupixent SyringeDupilumab25$93,985
Spiriva HandihalerTiotropium Bromide60$44,418
Breztri AerosphereBudesonide/Glycopyr/Formoterol49$35,557
Combivent RespimatIpratropium/Albuterol Sulfate58$31,855
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr68$30,651
Spiriva RespimatTiotropium Bromide39$29,663
Stiolto RespimatTiotropium Br/Olodaterol Hcl20$13,941
Breo ElliptaFluticasone/Vilanterol30$13,545
Albuterol Sulfate HfaAlbuterol Sulfate421$13,256
Atrovent HfaIpratropium Bromide18$13,089
SymbicortBudesonide/Formoterol Fumarate41$12,924
EliquisApixaban13$8,244
DuleraMometasone/Formoterol15$5,298

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta$683$260,018361 claims
Boehringer IngelheimCombivent Respimat, Spiriva Respimat, Stiolto Respimat$758$75,458117 claims
AstraZenecaBreztri Aerosphere, Symbicort$500$48,48090 claims
PfizerEliquis$15$8,24413 claims
MerckDulera$166$5,29815 claims
Teva Pharmaceuticals USA, Inc.Qvar Redihaler$19$3,95513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,261 pulmonary disease providers in California.

Other pulmonary disease in Placerville

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →